Calamos Advisors LLC Has $20.48 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Calamos Advisors LLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 252,818 shares of the biopharmaceutical company’s stock after selling 4,767 shares during the quarter. Calamos Advisors LLC’s holdings in Gilead Sciences were worth $20,481,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of GILD. Altfest L J & Co. Inc. purchased a new stake in Gilead Sciences in the 4th quarter worth about $210,000. Federated Hermes Inc. grew its holdings in Gilead Sciences by 4.9% during the 4th quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock valued at $306,814,000 after buying an additional 175,925 shares in the last quarter. Abundance Wealth Counselors purchased a new stake in shares of Gilead Sciences in the third quarter worth about $1,881,000. Toronto Dominion Bank boosted its position in shares of Gilead Sciences by 66.6% in the third quarter. Toronto Dominion Bank now owns 1,288,884 shares of the biopharmaceutical company’s stock valued at $96,589,000 after acquiring an additional 515,191 shares during the period. Finally, Mackenzie Financial Corp grew its stake in Gilead Sciences by 8.9% during the fourth quarter. Mackenzie Financial Corp now owns 535,557 shares of the biopharmaceutical company’s stock valued at $43,385,000 after acquiring an additional 43,630 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Up 0.4 %

Shares of Gilead Sciences stock traded up $0.27 during trading on Friday, hitting $66.43. The company’s stock had a trading volume of 906,160 shares, compared to its average volume of 7,221,661. The company has a market capitalization of $82.71 billion, a PE ratio of 14.70, a P/E/G ratio of 0.92 and a beta of 0.19. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. Gilead Sciences, Inc. has a 52 week low of $65.90 and a 52 week high of $87.86. The company has a fifty day simple moving average of $72.10 and a two-hundred day simple moving average of $76.58.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The firm had revenue of $7.12 billion for the quarter, compared to the consensus estimate of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The firm’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.67 earnings per share. Equities research analysts predict that Gilead Sciences, Inc. will post 6.55 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were paid a dividend of $0.77 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 dividend on an annualized basis and a yield of 4.64%. The ex-dividend date was Thursday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 68.44%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on GILD. Oppenheimer decreased their target price on shares of Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, February 12th. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 26th. Mizuho cut their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Truist Financial cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and cut their price objective for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Finally, Wells Fargo & Company dropped their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research report on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $84.71.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.